STUDY OBJECTIVE: To analyse the relation between coffee consumption and mutations in the K-ras gene in exocrine pancreatic cancer. DESIGN: Case-case study. Consumption of coffee among cases with the activating mutation in the K-ras gene was compared with that of cases without the mutation. SETTING AND PATIENTS: All cases of pancreatic cancer newly diagnosed at five hospitals in Spain during three years were included in the PANKRAS II Study (n = 185, of whom 121 whose tissue was available for molecular analysis are the object of the present report). Over 88% were personally interviewed in hospital. DNA was amplified from paraffin wax embedded tissues, and mutations in codon 12 of K-ras were detected by the artificial RFLP technique. MAIN RESULTS: Mutations were found in tumours from 94 of 121 patients (77.7%). Mutations were more common among regular coffee drinkers than among non-regular coffee drinkers (82.0% v 55.6%, p = 0.018, n = 107). The odds ratio adjusted by age, sex, smoking and alcohol drinking was 5.41 (95% CI 1.64, 17.78). The weekly intake of coffee was significantly higher among patients with a mutated tumour (mean of 14.5 cups/week v 8.8 among patients with a wild type tumour, p < 0.05). With respect to non-regular coffee drinkers, the odds ratio of a mutated tumour adjusted by age, sex, smoking and alcohol drinking was 3.26 for drinkers of 2-7 cups/week, 5.77 for drinkers of 8-14 cups/week and 9.99 for drinkers of > or = 15 cups/week (p < 0.01, test for trend). CONCLUSIONS: Pancreatic cancer cases without activating mutations in the K-ras gene had drank significantly less coffee than cases with a mutation, with a significant dose response relation: the less they drank, the less likely their tumours were to harbour a mutation. In exocrine pancreatic cancer the K-ras gene may be activated less often among non-regular coffee drinkers than among regular drinkers. Caffeine, other coffee compounds or other factors with which coffee drinking is associated may modulate K-ras activation.
STUDY OBJECTIVE: To analyse the relation between coffee consumption and mutations in the K-ras gene in exocrine pancreatic cancer. DESIGN: Case-case study. Consumption of coffee among cases with the activating mutation in the K-ras gene was compared with that of cases without the mutation. SETTING AND PATIENTS: All cases of pancreatic cancer newly diagnosed at five hospitals in Spain during three years were included in the PANKRAS II Study (n = 185, of whom 121 whose tissue was available for molecular analysis are the object of the present report). Over 88% were personally interviewed in hospital. DNA was amplified from paraffin wax embedded tissues, and mutations in codon 12 of K-ras were detected by the artificial RFLP technique. MAIN RESULTS: Mutations were found in tumours from 94 of 121 patients (77.7%). Mutations were more common among regular coffee drinkers than among non-regular coffee drinkers (82.0% v 55.6%, p = 0.018, n = 107). The odds ratio adjusted by age, sex, smoking and alcohol drinking was 5.41 (95% CI 1.64, 17.78). The weekly intake of coffee was significantly higher among patients with a mutated tumour (mean of 14.5 cups/week v 8.8 among patients with a wild type tumour, p < 0.05). With respect to non-regular coffee drinkers, the odds ratio of a mutated tumour adjusted by age, sex, smoking and alcohol drinking was 3.26 for drinkers of 2-7 cups/week, 5.77 for drinkers of 8-14 cups/week and 9.99 for drinkers of > or = 15 cups/week (p < 0.01, test for trend). CONCLUSIONS:Pancreatic cancer cases without activating mutations in the K-ras gene had drank significantly less coffee than cases with a mutation, with a significant dose response relation: the less they drank, the less likely their tumours were to harbour a mutation. In exocrine pancreatic cancer the K-ras gene may be activated less often among non-regular coffee drinkers than among regular drinkers. Caffeine, other coffee compounds or other factors with which coffee drinking is associated may modulate K-ras activation.
Authors: M Soler; M Porta; N Malats; L Guarner; S Costafreda; J M Gubern; E García-Olivares; M Andreu; F X Real Journal: J Clin Epidemiol Date: 1998-12 Impact factor: 6.437
Authors: D T Silverman; C A Swanson; G Gridley; S Wacholder; R S Greenberg; L M Brown; R B Hayes; G M Swanson; J B Schoenberg; L M Pottern; A G Schwartz; J F Fraumeni; R N Hoover Journal: J Natl Cancer Inst Date: 1998-11-18 Impact factor: 13.506
Authors: Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real Journal: Clin Transl Oncol Date: 2005-06 Impact factor: 3.405
Authors: M Porta; S Costafreda; N Malats; L Guarner; M Soler; J M Gubern; E García-Olivares; M Andreu; A Salas; J M Corominas; J Alguacil; A Carrato; J Rifà; F X Real Journal: Eur J Epidemiol Date: 2000-06 Impact factor: 8.082
Authors: P Maisonneuve; A B Lowenfels; B Müllhaupt; G Cavallini; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf; L Frulloni; R W Ammann Journal: Gut Date: 2005-04 Impact factor: 23.059
Authors: Marta Crous-Bou; Immaculata De Vivo; Miquel Porta; José A Pumarega; Tomàs López; Joan Alguacil; Eva Morales; Núria Malats; Juli Rifà; David J Hunter; Francisco X Real Journal: Dig Dis Sci Date: 2008-03-18 Impact factor: 3.199
Authors: Brenda Eskenazi; Jonathan Chevrier; Lisa Goldman Rosas; Henry A Anderson; Maria S Bornman; Henk Bouwman; Aimin Chen; Barbara A Cohn; Christiaan de Jager; Diane S Henshel; Felicia Leipzig; John S Leipzig; Edward C Lorenz; Suzanne M Snedeker; Darwin Stapleton Journal: Environ Health Perspect Date: 2009-05-04 Impact factor: 9.031